tiprankstipranks
Crescent Biopharma (CBIO)
NASDAQ:CBIO
US Market
CBIO
Crescent Biopharma
RESEARCH TOOLSreports
Want to see CBIO full AI Analyst Report?

Crescent Biopharma (CBIO) Ratios

1,025 Followers

Crescent Biopharma Ratios

CBIO's free cash flow for Q1 2026 was $1.00. For the 2026 fiscal year, CBIO's free cash flow was decreased by $ and operating cash flow was $-22.41. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 13.78 6.56 3.62 6.41 5.71
Quick Ratio
 13.78 6.56 3.62 6.41 5.71
Cash Ratio
 13.33 5.91 3.62 6.11 5.39
Solvency Ratio
 -10.60 -4.13 -0.95 -5.32 -5.23
Operating Cash Flow Ratio
 -5.31 -1.98 -3.23 -5.10 -5.23
Short-Term Operating Cash Flow Coverage
 -166.36 -164.44 0.00 0.00 0.00
Net Current Asset Value
$ 180.28M$ 199.37M$ -16.29M$ 36.89M$ 41.83M
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 <0.01 1.05 0.02 0.02
Debt-to-Equity Ratio
 <0.01 <0.01 -2.42 0.02 0.02
Debt-to-Capital Ratio
 <0.01 <0.01 1.70 0.02 0.02
Long-Term Debt-to-Capital Ratio
 <0.01 <0.01 1.70 0.00 0.00
Financial Leverage Ratio
 1.08 1.18 -2.30 1.18 1.21
Debt Service Coverage Ratio
 -105.41 -57.89 -51.85 0.00 0.00
Interest Coverage Ratio
 -152.04 -69.85 -58.57 0.00 0.00
Debt to Market Cap
 <0.01 0.01 0.08 0.00 0.00
Interest Debt Per Share
 0.09 0.37 1.97 0.01 0.02
Net Debt to EBITDA
 1.18 1.41 -0.06 1.05 0.99
Profitability Margins
Gross Profit Margin
100.00%100.00%0.00%100.00%100.00%
EBIT Margin
-1338.08%-1381.01%0.00%-392746.56%-63203.84%
EBITDA Margin
-1336.83%-1380.24%0.00%-391213.55%-62927.65%
Operating Profit Margin
-1372.85%-1407.52%0.00%-392752.93%-63204.43%
Pretax Profit Margin
-1347.11%-1401.16%0.00%-368987.83%-62251.15%
Net Profit Margin
-1363.94%-1419.61%0.00%-368994.20%-62251.74%
Continuous Operations Profit Margin
-1363.94%-1419.61%0.00%-368987.83%-62251.15%
Net Income Per EBT
101.25%101.32%100.00%100.00%100.00%
EBT Per EBIT
98.12%99.55%97.25%93.95%98.49%
Return on Assets (ROA)
-81.39%-64.06%-136.24%-81.43%-90.11%
Return on Equity (ROE)
-100.86%-75.83%313.48%-96.06%-108.76%
Return on Capital Employed (ROCE)
-88.21%-74.74%-191.89%-102.06%-110.42%
Return on Invested Capital (ROIC)
-88.00%-74.58%-191.89%-100.13%-108.11%
Return on Tangible Assets
-81.39%-64.06%-136.24%-81.43%-90.11%
Earnings Yield
-28.74%-124.64%-9.99%-0.25%-0.29%
Efficiency Ratios
Receivables Turnover
 0.00 0.60 0.00 0.06 0.52
Payables Turnover
 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 5.16 4.68 0.00 0.01 0.10
Asset Turnover
 0.06 0.05 0.00 <0.01 <0.01
Working Capital Turnover Ratio
 0.06 0.10 0.00 <0.01 <0.01
Cash Conversion Cycle
 0.00 605.86 0.00 6.42K 700.88
Days of Sales Outstanding
 0.00 605.86 0.00 6.42K 700.88
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 0.00 0.00 0.00 0.00 0.00
Operating Cycle
 0.00 605.86 0.00 6.42K 700.88
Cash Flow Ratios
Operating Cash Flow Per Share
 -2.48 -6.87 -1.59 -0.55 -0.88
Free Cash Flow Per Share
 -4.88 -6.96 -1.60 -0.55 -0.89
CapEx Per Share
 2.40 0.09 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 1.97 1.01 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 -1.03 -77.84 -3.12K -1.63K -551.81
Capital Expenditure Coverage Ratio
 -1.03 -77.84 -3.12K -1.63K -551.81
Operating Cash Flow Coverage Ratio
 -48.84 -43.51 -0.83 -43.15 -50.58
Operating Cash Flow to Sales Ratio
 -6.34 -6.60 0.00 -3.49K -619.43
Free Cash Flow Yield
-29.02%-58.66%-6.41%-0.23%-0.29%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -3.75 -0.80 -10.01 -405.12 -340.92
Price-to-Sales (P/S) Ratio
 46.34 11.39 0.00 1.49M 212.23K
Price-to-Book (P/B) Ratio
 3.30 0.61 -31.37 389.15 370.77
Price-to-Free Cash Flow (P/FCF) Ratio
 -3.71 -1.70 -15.61 -428.32 -341.99
Price-to-Operating Cash Flow Ratio
 -8.05 -1.73 -15.61 -428.58 -342.61
Price-to-Earnings Growth (PEG) Ratio
 0.02 >-0.01 -0.07 11.63 12.33
Price-to-Fair Value
 3.30 0.61 -31.37 389.15 370.77
Enterprise Value Multiple
 -2.29 0.59 -11.05 -381.07 -336.26
Enterprise Value
 323.84M -88.04M 488.27M 14.91B 15.87B
EV to EBITDA
 -2.04 0.59 -11.05 -381.07 -336.26
EV to Sales
 27.25 -8.12 0.00 1.49M 211.60K
EV to Free Cash Flow
 -2.18 1.22 -15.70 -427.14 -340.98
EV to Operating Cash Flow
 -4.30 1.23 -15.70 -427.40 -341.60
Tangible Book Value Per Share
 6.05 19.49 -0.79 0.61 0.82
Shareholders’ Equity Per Share
 6.05 19.49 -0.79 0.61 0.82
Tax and Other Ratios
Effective Tax Rate
 -0.01 -0.01 0.00 0.00 0.00
Revenue Per Share
 0.39 1.04 0.00 <0.01 <0.01
Net Income Per Share
 -5.33 -14.78 -2.49 -0.58 -0.89
Tax Burden
 1.01 1.01 1.00 1.00 1.00
Interest Burden
 1.01 1.01 1.10 0.94 0.98
Research & Development to Revenue
 12.23 12.73 0.00 2.01K 378.55
SG&A to Revenue
 2.50 2.34 0.00 1.92K 254.49
Stock-Based Compensation to Revenue
 0.75 1.23 0.00 356.05 51.43
Income Quality
 0.46 0.48 0.82 0.95 1.00
Currency in USD